BiotechTube
Ariel Precision Medicine

Ariel Precision Medicine

Pittsburgh, United States· Est.
arielmedicine.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $8.5M

Overview

Ariel Precision Medicine is a private, pre-revenue biotech applying artificial intelligence to precision medicine for complex diseases. Its core asset is the ADVANCE platform, which analyzes deep genetic, clinical, and environmental data to identify novel disease subtypes and therapeutic targets. The company's lead program, APM-176, is a Phase 2-ready oral small molecule targeting multiple CFTR-related chronic conditions, positioning Ariel to address a significant unmet need in a validated biological pathway. The company's strategy hinges on using AI to de-risk drug development and personalize patient care.

GastroenterologyPulmonologyOtolaryngologyHepatology

Technology Platform

ADVANCE: A proprietary AI platform that integrates deep genetic sequencing, clinical data, lifestyle, and environmental factors to identify novel disease subtypes and biological mechanisms for personalized care and de-risked drug development.

Funding History

2
Total raised:$8.5M
Series A$6M
Seed$2.5M

Opportunities

Large, underserved patient populations across multiple CFTR-related disorders represent a significant market opportunity, validated by the success of CFTR modulators in cystic fibrosis.
Success with APM-176 would also validate the ADVANCE AI platform, creating asset value and potential for expansion into other complex disease areas.

Risk Factors

High clinical development risk as APM-176 must prove efficacy in new, heterogeneous indications.
The company's core value depends on the unproven ability of its ADVANCE AI platform to consistently de-risk development.
As a pre-revenue private company, it faces financing risk and potential competition from larger players.

Competitive Landscape

Ariel is a pioneer in targeting CFTR for non-CF diseases, a relatively nascent field. However, it competes indirectly with companies developing therapies for each individual indication (e.g., sinusitis, pancreatitis). Large pharma companies with CFTR expertise (e.g., Vertex, AbbVie) represent potential future competitors or partners.

More companies in Diagnostics & Precision Medicine →More companies in United States →